Brief: In Preparation For Expected Human Clinical Trials, Nurexone Signs Agreement For Large Scale Preclinical Testing For Its Spinal Cord Injury Therapy, Exopten
22/03/2024 21:08
March 22 (Reuters) - Nurexone Biologic Inc NRX.V :
* IN PREPARATION FOR EXPECTED HUMAN CLINICAL TRIALS,
NUREXONE
SIGNS AGREEMENT FOR LARGE SCALE PRECLINICAL TESTING FOR ITS
SPINAL CORD INJURY THERAPY, EXOPTEN
* NUREXONE BIOLOGIC INC: UNDER TERMS OF AGREEMENT, VIVOX
WILL
PROVIDE CONTRACT RESEARCH ORGANIZATION (CRO) SERVICES TO CO
Source text for Eikon: ID:nGNXBt7z2
Further company coverage: NRX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurexone Biologic
See all newsBrief: Nurexone Announces Binding MoU With Made Scientific For U.S. Gmp Manufacturing And Commercial Supply Partnership
Brief: Corporate Updates – Nurexone Appoints Mr. David Stolick To The Board Of Directors
Brief: Exo-Top, Nurexone’S Wholly Owned U.S. Subsidiary, Enters Into Binding MoU For Naïve Exosome Distribution In Mexico
Brief: Nurexone Biologic’S U.S. Subsidiary Exo-Top And Florida-Based Bioxtek Sign Strategic Loi For Exosome Manufacturing And Commercialization
Brief: Nurexone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement